Business Context and Reporting Period
This Form 6-K filing by Immuron Ltd (ASX: IMC) covers the month of July 2022, specifically dated July 26, 2022. The report serves to disseminate a public announcement made to the Australian Securities Exchange regarding the company's clinical development pipeline.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is an update on the Investigational New Drug (IND) application for the company's Campylobacter ETEC therapeutic. No financial performance changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the status of the IND application for the Campylobacter ETEC therapeutic. The filing does not provide specific forward-looking guidance, financial outlook, or a detailed discussion of risks and contingencies beyond the context of the regulatory update.
Key Facts for Investor Verification
- The company submitted an update on July 26, 2022, concerning its IND application for a Campylobacter ETEC therapeutic.
- The full details of the regulatory update are contained in the attached exhibit (Exhibit 99.1) titled "IMC - Update on IND Application for Campylobacter ETEC Therapeutic."
- This Form 6-K does not include financial results; investors should refer to the company's Form 20-F or interim reports for financial data.